Dihydroxyphenylalanine (Dopa)

A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.

Also Known As:

Networked: 1143 relevant articles (51 outcomes, 102 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Piccardo, Arnoldo: 6 articles (12/2015 - 01/2014)
2.	Goshima, Yoshio: 6 articles (03/2015 - 06/2002)
3.	Hussain, Khalid: 6 articles (12/2014 - 01/2006)
4.	Kirik, Deniz: 5 articles (05/2015 - 03/2005)
5.	Neumann, Hartmut P H: 5 articles (01/2014 - 02/2002)
6.	Brooks, David J: 5 articles (09/2013 - 10/2002)
7.	Lang, Anthony E: 5 articles (06/2013 - 03/2002)
8.	Rufini, Vittoria: 5 articles (06/2013 - 01/2011)
9.	Morana, Giovanni: 4 articles (12/2015 - 03/2014)
10.	Goldstein, David S: 4 articles (09/2015 - 08/2004)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 05/01/2001 - "Some of its properties are probably linked to high concentrations of dopa since it is useful in the treatment of Parkinson's disease. " 05/01/1996 - "With future improvement in the gene transduction procedure for more efficient, sustained expression of the TH transgene in vivo, genetically engineered DOPA-producing astrocytes hold great promise as a tool to explore the potential of ex vivo gene therapy in Parkinson's disease." 05/01/1992 - "F-dopa/PET holds particular promise in preclinical screening of individuals at risk for Parkinson's disease on genetic or environmental grounds. " 09/15/2011 - "The assay was employed to study the metabolism of DOPA, a well-known therapeutic drug for treating Parkinson's disease. " 08/01/2009 - "The aim of this study was to evaluate the effect of administration of levo-dopa, which means without effect-off state and under effect-on state, on the sternocleidomastoid muscle electromyographic activity (SCM-EA) in patients with Parkinson's disease (PD) at rest and to compare it to asymptomatic subjects. "
2.	Dyskinesias (Dyskinesia) 01/01/2009 - "The aim of this study was to detect the presence of gene GCH-I mutation in our population in patients with dopa-responsive dystonic dyskinesia and to analyse clinical specificity of the affected. " 05/01/2015 - "Current treatment and future prospects of dopa-induced dyskinesias." 11/01/2012 - "On the other end of the spectrum of the disease course, during later stages of PD, significant clinical challenges like levo-dopa-induced dyskinesias and medication on-off phenomenon become more prevalent. " 08/01/2004 - "However, after an initial period of dramatic benefit, several limitations become apparent including, "dopa resistant" motor symptoms (postural abnormalities, freezing episodes, speech impairment), "dopa resistant" non-motor signs (autonomic dysfunction, mood and cognitive impairment, etc), and/or drug related side effects (especially psychosis, motor fluctuations, and dyskinesias). " 12/01/2001 - "Dopa-induced dyskinesia can be attenuated effectively by the direct and/or indirect effects of DBS therapy. "
3.	Neoplasms (Cancer) 10/01/2009 - "6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess." 10/01/2009 - "The objective of the study was to investigate the sensitivity of 6-[F-18]fluoro-l-dihydroxyphenylalanine positron emission tomography ((18)F-DOPA PET), compared with (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy and computer tomography (CT)/magnetic resonance imaging (MRI) for tumor localization in patients with catecholamine excess. " 02/01/1984 - "However, the DOPA reaction was also negative in an amelanotic recurrent tumor of a melanotic CCS, and electron-microscopic studies revealed a close resemblance between amelanotic CCS and melanotic CCS. " 06/01/2015 - "We have suggested a protocol in which SRS is replaced by one of the two agents (preferably with (68)Ga-DOTA-SSTa, alternatively (18)F-DOPA) as first-line nuclear tracer for detection of CUP-NET in patients with well-differentiated NETs and (18)F-FDG PET/CT may be an additional diagnostic test for poorly differentiated tumors and for prognostication. " 01/01/2015 - "However, F-DOPA-PET, which is related to amine precursor uptake by NETs, has been reported to have high positive predictive value for occult EAS despite low sensitivity, and constitutes a useful alternative to more conventional methods of tumor localization. "
4.	Dystonia (Limb Dystonia) 03/01/1995 - "Remission in dihydroxyphenylalanine-responsive dystonia." 06/15/2011 - "We interrogated the complete genome sequences of a 14-year-old fraternal twin pair diagnosed with dopa (3,4-dihydroxyphenylalanine)-responsive dystonia (DRD; Mendelian Inheritance in Man #128230). " 06/05/2010 - "High frequency of multiexonic deletion of the GCH1 gene in a Taiwanese cohort of dopa-response dystonia." 03/01/2005 - "The combination of symptoms, their sensitivity to DOPA, and their persistence throughout childhood constitute, to our knowledge, a new clinical entity, which we propose to categorize as a DOPA-sensitive dystonia-plus syndrome." 03/01/2005 - "DOPA-sensitive dystonia-plus syndrome."
5.	Parkinsonian Disorders (Parkinsonism) 10/01/2002 - "We have used [(18)F]dopa PET serially to study members of a family with young-onset parkinsonism who are compound heterozygous for mutations in the parkin gene, having an exonic deletion and a novel intronic splice site mutation. " 11/01/1992 - "The identification of presymptomatic parkinsonism: clinical and [18F]dopa positron emission tomography studies in an Irish kindred." 09/01/2015 - "All conditions involving parkinsonism had accelerated loss of putamen (18)F-DOPA-derived radioactivity; in those with post-mortem data there were also decreased putamen DA:DOPA ratios. " 02/01/2013 - "Parkinsonism with dopa-sensitivity and a correlating DaTSCAN turned out to be due to a D202N mutation which is associated with the Gerstmann-Sträussler-Scheinker (GSS) disease. " 10/01/2012 - "There was an overall negative correlation between the degree of parkinsonism (Kurlan scale) and in vivo PET ((18)F-DOPA K(i) and (11)C-DTBZ binding potential), as well as with TH-immunoreactive cell counts in SNc, striatal dopaminergic markers (TH, DAT and VMAT2) and striatal DA concentration. "

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	Dopamine (Intropin)
3.	Dihydroxyphenylalanine (Dopa)
4.	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)
5.	Catecholamines
6.	Methyldopa (Aldomet)
7.	5-Hydroxytryptophan (5 Hydroxytryptophan)
8.	Serotonin (5 Hydroxytryptamine)
9.	Enzymes
10.	3,4-Dihydroxyphenylacetic Acid

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Radiotherapy
3.	Pallidotomy
4.	Aftercare (After-Treatment)
5.	Deep Brain Stimulation